Grass Pollen Allergy Study Earn Up to 6100 Dollar
| Date: | 15-Nov-15 to 30-Nov-15 |
| Location: | Multiple locations to participate in NY and NJ / New York / United States |
| Category: | Education |
We pay participants to be part of this study. Participants can earn up to $6,100 if they successfully complete the study and its requirements.
Multiple locations to participate in NY and NJ
Ages 18-50, people who experience grass pollen allergy symptoms in the summer time, people who require medication for their symptoms but find that medications are not effective at controlling symptoms.
For more details please visit http://www.Pollenstudy.com or call at 905-282-1808, or 888-989-1808 (toll-free does not work in all regions)
Description of Project:
This is a randomized, double-blinded, placebo controlled study investigating Grass MATA MPL in the form of subcutaneous injections (needle injections given just under the skin), which has been developed by the study sponsor, Allergy Therapeutics (UK) Ltd., for the treatment of grass pollen allergy. The course of study treatment injections is designed to provide specific immunity to (protection against) grass pollen allergy for the long term relief of symptoms like runny, stuffy nose, sneezing, and itchy, watery eyes when exposed to grass pollens. Your participation in this clinical study is entirely voluntary. You can only take part in this study after you have given your written consent. Before you make any decisions, it is important for you to understand why the research is being done and what it will involve. You will be compensated up to $6,100 for completing the study in its entirety. In total there are 16 clinic visits + 4 telephone calls.
This study utilizes Inflamax Research’s mobile Environmental Exposure Chamber, referred to as EEC, to bring on allergy symptoms in a controlled manner. You are required to attend two, four day sessions, at either the Cincinnati, Ohio, or Neptune, New Jersey EEC. At the EEC you will answer questions about your allergy symptoms inside the EEC. Each EEC session will last for 3 hours, and the total time at the site will be approximately 4.5hrs per day.
Multiple locations to participate in NY and NJ
Ages 18-50, people who experience grass pollen allergy symptoms in the summer time, people who require medication for their symptoms but find that medications are not effective at controlling symptoms.
For more details please visit http://www.Pollenstudy.com or call at 905-282-1808, or 888-989-1808 (toll-free does not work in all regions)
Description of Project:
This is a randomized, double-blinded, placebo controlled study investigating Grass MATA MPL in the form of subcutaneous injections (needle injections given just under the skin), which has been developed by the study sponsor, Allergy Therapeutics (UK) Ltd., for the treatment of grass pollen allergy. The course of study treatment injections is designed to provide specific immunity to (protection against) grass pollen allergy for the long term relief of symptoms like runny, stuffy nose, sneezing, and itchy, watery eyes when exposed to grass pollens. Your participation in this clinical study is entirely voluntary. You can only take part in this study after you have given your written consent. Before you make any decisions, it is important for you to understand why the research is being done and what it will involve. You will be compensated up to $6,100 for completing the study in its entirety. In total there are 16 clinic visits + 4 telephone calls.
This study utilizes Inflamax Research’s mobile Environmental Exposure Chamber, referred to as EEC, to bring on allergy symptoms in a controlled manner. You are required to attend two, four day sessions, at either the Cincinnati, Ohio, or Neptune, New Jersey EEC. At the EEC you will answer questions about your allergy symptoms inside the EEC. Each EEC session will last for 3 hours, and the total time at the site will be approximately 4.5hrs per day.
EIN News
provides powerful, real-time media monitoring, news aggregation & syndication services. Read the latest news about this topic. See:
